Molecular Mechanisms of Combination Adjuvants (MMCA)(U01)

Post Date

February 10th 2015

Application Due Date

July 9th 2015

Funding Opportunity Number

RFA-AI-15-005

CFDA Number(s)

93.855
93.856

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $4000000

• Award Range:

  $None - $350000

Grant Description

This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are used in these studies must already have shown immune boosting activity when used individually in licensed or unlicensed vaccines (e.g. experimental or candidate vaccines). The purpose of this FOA is to build upon the investment the NIAID has already made into adjuvant research, by combining previously identified and characterized adjuvants and characterizing their immune stimulating activity. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAIDs overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations which will improve the immunogenicity of vaccines while addressing concerns related to reactogenicity.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-15-005.html